SKAP2-BRAF fusion
|
Melanoma
|
SKAP2-BRAF fusion
|
Melanoma
|
pembrolizumab + nivolumab + trametinib + ipilimumab + dacarbazine Resistant: C4 – Case Studies
|
pembrolizumab + nivolumab + trametinib + ipilimumab + dacarbazine Resistant: C4 – Case Studies
|
SKAP2-BRAF fusion
|
Melanoma
|
SKAP2-BRAF fusion
|
Melanoma
|
PLX8394 Resistant: D – Preclinical
|
PLX8394 Resistant: D – Preclinical
|
SKAP2-BRAF fusion
|
Melanoma
|
SKAP2-BRAF fusion
|
Melanoma
|
dabrafenib Resistant: D – Preclinical
|
dabrafenib Resistant: D – Preclinical
|
SKAP2-BRAF fusion
|
Melanoma
|
SKAP2-BRAF fusion
|
Melanoma
|
vemurafenib Resistant: D – Preclinical
|
vemurafenib Resistant: D – Preclinical
|